
(12) **UK Patent Application** (19) **GB** (11) **2 120 548 A**

(21) Application No 8311592
(22) Date of filing 28 Apr 1983
(30) Priority data
(31) 372844
(32) 29 Apr 1982
(33) United States of America
(US)

(43) Application published
7 Dec 1983

(51) INT CL³
A61K 35/74 31/70

(52) Domestic classification
A5B 180 230 23Y 26Y
30X 30Y 323 32Y 38Y
39X 822 J L

(56) Documents cited
US 3932943
US 3594471
US 4134214
Immunotherapy with Non-
viable Microbrat
Components Ribi et al
Annals of the National
Academy of Sciences,
Volume 227, pages
228—238, September
20th 1976

(58) Field of search
A5B

(71) Applicant
Ribi Immunochem
Research Inc.
(USA—Montana),
Box 1409, Hamilton,
Montana 59840, United
States of America

(72) Inventors
Edgar Ernst Ribi,
John Leonard Cantrell,
Steven Marc
Schwartzman

(74) Agent and/or Address for
Service
Withers and Rogers,
4 Dyer's Buildings,
Holborn, London
EC1N 2JT

(54) **Anti-tumour microorganism
obtained products**

(57) **A stable composition containing
cell wall skeleton (CWS) trehalose**

dimycolates (TDM), and a light
hydrocarbon non-biodegradable oil
e.g. mineral oil which may be
effectively reconstituted to an
emulsion after lyophilization.

BEST AVAILABLE COPY

GB 2 120 548 A

SPECIFICATION

Stable composition and preparation thereof

The subject matter of the present invention is directed to a stable, therapeutically effective composition containing cell wall skeleton (CWS) and purified trehalose dimycolates (TDM). Both substances are isolates of bacteria and when used together as a composition, are effective in obtaining suppression and regression of tumor cells. The present invention also includes a method of preparing the composition as well as use of the composition in treating cancerous tumors and as an adjuvant.

The combination of CWS and TDM is known in the art (see *Biologically Active Components from Mycobacterial Cell Walls. II. Suppression and Regression of Strain-2 Guinea Pig Hepatoma*; Meyer et al., *Journal of the National Cancer Institute*, Volume 52, No. 1, January, 1974; and *Mycobacterial Cell Wall Components in Tumor Suppression and Regression*; Ribí et al., National Cancer Institute Monograph No. 39, pp. 115—120, October, 1972) incorporated herein by reference.

Cell Wall Skeleton is essentially cell wall which has had much of the protein and lipids normally found in the cell wall removed. It is a polymeric mycolic acid-arabinogalactan mucopeptide containing remnants of trehalose mycolates ("P₃") and undigested tuberculo-proteins. Cell wall skeleton is obtained from any mycobacteria including, but not limited to, *M. smegmatis*, *M. phlei*, *M. avium*, *Nocardia rubra*, *Nocardia asteroides*, *Corynebacterium diphtheriae*, *Corynebacterium parvum*, *M. bovis*, *M. kansasii*, *M. tuberculosis* (Strain H 37 RV and Ayoma B), and *M. bovis* Strain BCG. Additionally, cell wall skeleton may be obtained from such non-mycobacteria as *E. coli*, *B. abortus* and *Coxiella burnettii*.

The process of producing cell wall skeleton is time consuming. The bacteria such as *M. bovis* Strain BCG (Bacillus Calmette-Guerin) is grown and harvested. The resulting whole cell residue is processed through a cell fractionator Ribí Cell Fractionator (Sorvall, Model RF-1) which disrupts the cells, separating the outer envelope of cell wall from the protoplasmic impurities. The resulting cell walls are then subjected to a series of solvent extractions and enzymatic treatments (e.g., trypsin and/or chymotrypsin) to give purified cell wall skeleton.

The second component of the instant composition, trehalose dimycolates (TDM), may be obtained from any mycobacteria as, for example, *M. avium*, *M. phlei*, *M. tuberculosis* (Strain H 37 RV and Ayoma B), *M. bovis* BCG, *M. smegmatis*, *M. kansasii*, *Nocardia rubra*, *M. bovis* and *Corynebacterium diphtheriae*.

Bacteria such as *M. avium* is grown, harvested and then heat killed. The cell mass is then extracted with several solvents and then an active, solvent soluble, fraction is extracted. This extract is further purified by a series of solvent extractions to provide crude TDM (see *Biologically Active Components from Mycobacterial Cell Walls. I. Isolation and Composition of Cell Wall Skeleton and Component P₃*; Azuma et al., *Journal of the National Cancer Institute*, Volume 52, pp. 95—101, 1974) incorporated herein by reference. As disclosed in Azuma et al., crude TDM may then be further purified by centrifugal microparticulate silica gel chromatography to give purified TDM.

CWS and TDM produced as described above have been combined in an oil droplet emulsion. The non-living components are ground with a small amount of mineral oil and emulsified in saline to produce an anti-tumor composition suitable for injection (see *Immunotherapy with Non-viable Microbial Components*; Ribí et al., *Annals of the National Academy of Sciences*, Volume 227, pp. 228—238, September 20th, 1976) incorporated herein by reference.

However, the prior art oil in saline emulsions containing CWS and TDM suffer from a major disadvantage. The emulsion has a relatively short shelf life at room temperature and, therefore, must be used shortly after preparation to produce the desired results.

It is well-known in the art that lyophilizing a pharmaceutical preparation can extend shelf life considerably (see, for example, USP 3,932,943; USP 3,594,471; and USP 4,134,214). To be successful, the lyophilized product must be able to be reconstituted at a later time without any loss in potency, that is, with the same potency as the pre-lyophilized product. However, the prior art CWS-TDM oil in saline emulsions have not been effectively lyophilized. Applicants have discovered that if these emulsions are not stabilized without delay, as, for example, by lyophilization, they will begin a process of degradation resulting in a significant percent of oil droplets becoming uncoated. The uncoated material is not active in tumor regression. The therapeutically effective emulsion of the present invention is stabilized by a lyophilization procedure; other stabilization procedures can also be utilized.

It is therefore an object of the invention to provide a stable CWS-TDM composition which may be effectively reconstituted to produce an effective anti-tumor preparation having a superior shelf life that is, a shelf life of a year and even longer. It is another object of the invention to provide a CWS-TDM composition having a large number of coated oil droplets which are very effective in tumor regression, without side effects.

It is still another object of the invention to provide a method of treating various cancer tumors with a stable and potent CWS-TDM composition. It is another object of the invention to employ the CWS-TDM composition as an adjuvant as for example, to increase the immune response to immunogens including, for example, microorganisms, proteins, carbohydrates, allergens, viruses and the like.

THE INVENTION

The present invention is directed to a stable composition comprising CWS and TDM in which the active materials are coated on oil droplets. The composition may be effectively reconstituted in an aqueous solution with the same potency as in the pre-lyophilized state.

5 The process of producing the instant composition comprises mixing CWS and TDM for a time sufficient to form a uniform suspension. If desirable, the TDM may be dissolved in a suitable solvent known to those skilled in the art. For example, such solvents include chloroform, ether, methanol, ethanol, combinations thereof and the like. The weight ratio of CWS to TDM is in the range of between about 1.0 and 6:1, preferably between about 2.5 and 3.0:1.

10 A light, non-biodegradable oil is then added and the resulting mixture is homogenized to form a paste-like substance.

The use of a light hydrocarbon non-biodegradable oil is an essential element of the process since biodegradable oils do not achieve the objects of the invention. Furthermore, the oil must be light weight typically having a viscosity of between about 8 and 12 centistokes measured at 100°F. Preferably, the viscosity is in the range of between about 10 to 10.6 centistokes.

15 The amount of oil used in the process is in the range of between about 0.5 and 3.0 percent by volume based on the total volume of the composition. It is preferred to use between about 0.75 and 1.5 percent by volume of the oil. Examples of such oils include light mineral oil, squalane, 7-n-hexyloctadecane, Conoco superoil and Drakeol 6 VR mineral oil (produced by the Pennreco Company, Butler, Pennsylvania).

20 The homogenized oil containing mixture is then combined with a detergent which may optionally be dissolved in a saline solution prior to mixing. The amount of detergent is typically between about 0.02 and 0.20 percent by volume and preferably between about 0.10 and 0.20 percent by volume based on the total volume of the composition. Any common detergent material may be used including Tween-80, and Arlacel (produced by the Atlas Chemical Company).

25 The mixture resulting from the addition of detergent is then homogenized to form a suspension which has a high percentage of oil droplets coated with CWS and TDM as determined by observation under a microscope.

30 The novel composition of the present invention is an effective agent in the treatment of cancerous tumors in humans and animals and the composition, in the form of an oil droplet emulsion, is injected directly into the tumor tissue. Cancers which can be treated include bovine fibrosarcoma, equine sarcoid, equine melanoma, canine melanoma, bovine ocular sarcoma, etc. The daily dosage of the composition to a typical adult patient weighing about 70 kilograms is sufficient to provide about 150—300 µg of CWS and 50—100 µg of TDM. Therapy may be continued for approximately two to six months providing a total dosage of up to 15 mg of CWS and 15 mg of TDM.

35 The instant composition, when used to increase a response to immunogens, is administered at a dosage of between about 10 and 500 micrograms. CWS and TDM can also be used separately as adjuvants; each in amounts of about 10 to about 500 micrograms.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

40 The following examples are for illustration purposes only and are not intended to limit or in any way redefine the invention as claimed in the claims appended hereto.

EXAMPLE 1 — PREPARATION OF CWS-TDM COMPOSITION

150 mg of CWS were introduced into a 350 ml tissue homogenizer (Belco). 50 mg of TDM were dissolved in 2.5 ml of a 95:5 chloroform-methanol mixture and then added to the homogenizer. The resulting CWS-TDM suspension was mixed for about 15 to 30 seconds and the solvent was evaporated using a sterile air stream. This was followed by the addition of 2 ml of sterile Drakeol 6 VR mineral oil (Pennreco Company, Butler, Pennsylvania) and the mixture was homogenized for 1 minute using a drill press while an oil paste consistency is obtained. 190 ml of 0.2 percent Tween-80 in saline solution was introduced into each homogenizer. Using a drill press, the mixture was homogenized for about 4 to 5 minutes until an emulsion was obtained. Microscopic investigation showed that substantially all of the oil droplets were coated with CWS and TDM.

EXAMPLE 2 — LYOPHILIZING THE CWS-TDM COMPOSITION

5 ml of the CWS-TDM oil in saline emulsion (a 1% oil-in-water emulsion) produced in accordance with the procedure of Example 1 was introduced into a 10 ml Wheaton serum vial. The vial was frozen in a Revoc freezer at a temperature of -95°C and lyophilized in a sterile container on a Labconco freeze dryer. The vial was then capped using a sterile technique.

EXAMPLE 3 — RECONSTITUTION OF LYOPHILIZED CWS-TDM COMPOSITION

60 A vial containing the lyophilized CWS-TDM emulsion produced in accordance with the procedure of Example 2 containing, for example, 3.75 mg CWS and 1.25 mg TDM in 5 ml of a 1% oil droplet emulsion was injected with sterile distilled water using a No. 20 gauge sterile syringe. The suspension was then emulsified by repeated aspirations and injections using the syringe for at least two minutes

until the resulting emulsion gave a cloudy-milky appearance.

EXAMPLE 4 — CWS-TDM COMPOSITION — COMPARISON DATA (ANIMALS)

5		Dose per animal (μ g) (guinea pig)*	Animals treated	% Regression	5
	CWS + TDM	300 + 150	125	76	
	CWS	300	157	46	
	CWS + TDM	150 + 150	56	63	
	CWS	150	65	43	
10	CWS + TDM	50 + 50	16	19	10
	CWS	50	40	10	
	TDM	150	39	3	
	TDM	100	22	0	
15	Oil-tween-saline controls	—	66	0	15

* Strain 2.

The CWS was obtained from *M. bovis*.

EXAMPLE 5 — CWS-TDM COMPOSITION — CLINICAL TEST RESULTS

17 adult patients afflicted with metastatic malignant melanoma were treated with doses of 300 to 20 1050 μ g of CWS (obtained from *M. smegmatis*) and 150 to 525 μ g TDM for 1 to 2 weeks for a total of 20 8 treatments. This therapy was effective in 7 patients; of the 7 patients, 6 had complete regression of at least 1 injected lesion.

CLAIMS

- 25 1. A method for producing a stable composition containing cell wall skeleton (CWS) and trehalose dimycolate (TDM) comprising: 25
- (a) mixing CWS and TDM;
- (b) adding a light hydrocarbon non-biodegradable oil to the resulting mixture;
- (c) homogenizing the resulting oil containing mixture;
- 30 (d) adding a detergent to said homogenized oil containing mixture; 30
- (e) homogenizing the resulting mixture to form a suspension containing oil droplets coated with CWS and TDM; and 30
- (f) lyophilizing the resulting emulsion.
2. The method of Claim 1, wherein the weight ratio of CWS to TDM is in the range of between about 1.0 and 6:1 and preferably between about 2.5:1 and 3.5:1.
- 35 3. The method of Claim 1, or 2, wherein said light hydrocarbon non-biodegradable oil has a viscosity of between about 8 and 12 centistokes measured at 100°F and preferably between about 10 and 10.6. 35
4. The method of any of the preceding claims wherein said light hydrocarbon non-biodegradable oil is present in an amount between about 0.5 and 3.0 percent by volume based on the total volume of 40 the composition and preferably between about 0.75 and 1.5 percent. 40
5. The method of any of the preceding claims wherein the amount of said detergent is between about 0.02 and 0.20 percent by volume based on the total volume of the composition and preferably between about 0.10 and 0.20 percent.
6. The method of any of the preceding claims wherein said detergent is dissolved in a saline 45 solution. 45
7. The method of any of the preceding claims wherein said cell wall skeleton is obtained from mycobacteria include *M. avium*, *M. phlei*, *M. tuberculosis* (Strain H 37 RV and Ayoma B), *M. bovis* BCG, *M. smegmatis*, *M. kansasii*, *Nocardia asteroides*, *Nocardia rubra*, *M. bovinis*, *Corynebacterium parvum* and *Corynebacterium diphtheriae*.
- 50 8. The method of any of the preceding claims further comprising reconstituting said lyophilized emulsion in the presence of an aqueous solution. 50

9. A method according to any of the preceding claims wherein said trehalose dimycolates are obtained from mycobacteria and said mycobacteria are selected from the group consisting of *M. avium*, *M. phlei*, *M. tuberculosis* (Strain H 37 RV and Ayoma B), *M. bovis* BCG, *M. smegmatis*, *M. kansasii*, *Nocardia rubra*, *M. bovinis* and *Corynebacterium diphtheriae*.
- 5 10. A method for producing a stable composition containing cell wall skeleton and trehalose dimycolate substantially as described herein. 5
11. The stable composition containing cell wall skeleton and trehalose dimycolate whenever obtained by a process according to any of the preceding claims.
- 10 12. A therapeutic composition comprising a lyophilized CWS, TDM in a weight ratio of between about 1.0 and 6:1 and a light hydrocarbon non-biodegradable oil and preferably said weight ratio is between about 2.5:1 and 3.5:1. 10
13. The reconstituted product of Claim 11.
14. A method of treating cancerous tumors comprising administering a therapeutically effective amount of the composition of Claim 12 or 13 to a warm blooded animal.
- 15 15. The method of Claim 14 wherein said therapeutic amount of the composition is between 150—300 μ g of CWS and between about 50—100 μ g of TDM. 15
16. The method of Claim 14 or 15 wherein said cancerous tumors are selected from bovine fibrosarcoma, equine sarcoid, equine melanoma, canine melanoma, or bovine ocular sarcoma.
- 20 17. The method of any of Claims 14—16 wherein said composition is administered in the form of an oil droplet emulsion. 20
18. A method of increasing the immune response to an immunogen comprising administering a therapeutically effective amount of the composition of Claim 12 or 13 to a warm blooded animal.
19. The method of Claim 18 further comprising administering said composition in an amount between about 10 and 500 μ g.
- 25 20. The method of Claim 18 or 19 wherein said composition is administered in the form of an oil droplet emulsion. 25

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.